Mitotane(continued)
▶Mitotaneis predicted to decrease the exposure topaliperidone.
Monitor and adjust dose.rStudy
▶Mitotaneis predicted to decrease the exposure to
panobinostat. Avoid.oTheoretical→Also seeTABLE 15
p. 850
▶Mitotaneis predicted to decrease the exposure toparitaprevir
(with ritonavir and ombitasvir). Avoid.rStudy
▶Mitotaneis predicted to decrease the exposure topazopanib.
Avoid.rTheoretical→Also seeTABLE 15p. 850
▶Mitotaneis predicted to decrease the exposure to
phosphodiesterase type-5 inhibitors(avanafil, tadalafil). Avoid.
rStudy
▶Mitotaneis predicted to decrease the exposure to
phosphodiesterase type-5 inhibitors(sildenafil, vardenafil).
oTheoretical
▶Mitotaneis predicted to moderately to markedly decrease the
exposure topibrentasvir. Avoid.rStudy
▶Mitotaneis predicted to moderately decrease the exposure to
pitolisant.oStudy
▶Mitotaneis predicted to decrease the exposure toponatinib.
Avoid.oTheoretical
▶Mitotaneis predicted to markedly decrease the exposure to
praziquantel. Avoid.oStudy
▶Mitotaneis predicted to decrease the exposure toquetiapine.
oStudy
▶Mitotaneis predicted to decrease the exposure toranolazine.
Avoid.rStudy
▶Mitotaneis predicted to decrease the exposure toreboxetine.
oAnecdotal
▶Mitotaneis predicted to decrease the exposure toregorafenib.
Avoid.oStudy→Also seeTABLE 15p. 850
▶Mitotaneis predicted to decrease the exposure torepaglinide.
Monitor blood glucose and adjust dose.oStudy
▶Mitotaneis predicted to markedly decrease the exposure to
ribociclib. Avoid.rStudy
▶Mitotanemarkedly decreases the exposure torilpivirine.
Avoid.rStudy
▶Mitotaneis predicted to decrease the exposure torisperidone.
Adjust dose.oStudy
▶Mitotaneis predicted to moderately decrease the exposure to
rivaroxaban. Avoid unless patient can be monitored for signs
of thrombosis.rStudy
▶Mitotaneis predicted to decrease the exposure toroflumilast.
Avoid.oStudy
▶Mitotaneis predicted to markedly decrease the exposure to
rolapitant. Avoid.rStudy
▶Mitotaneis predicted to decrease the exposure toruxolitinib.
Monitor and adjust dose.oStudy→Also seeTABLE 15
p. 850
▶Mitotaneis predicted to moderately decrease the exposure to
saxagliptin.oStudy
▶Mitotaneis predicted to decrease the exposure tosimeprevir.
Avoid.rStudy
▶Mitotaneis predicted to decrease the concentration of
sirolimus. Avoid.rStudy
▶Mitotaneis predicted to decrease the exposure tosolifenacin.
oTheoretical
▶Mitotaneis predicted to decrease the exposure tosorafenib.
oTheoretical→Also seeTABLE 15p. 850
▶Mitotaneis predicted to decrease the exposure tostatins
(simvastatin).rStudy
▶Mitotaneis predicted to decrease the exposure tosunitinib.
Avoid or adjustsunitinibdose.oStudy→Also see
TABLE 15p. 850
▶Mitotanedecreases the concentration oftacrolimus. Monitor
and adjust dose.rStudy
▶Mitotaneis predicted to decrease the exposure totaxanes
(cabazitaxel, paclitaxel). Avoid.rStudy→Also seeTABLE 15
p. 850
▶Mitotaneis predicted to decrease the exposure totaxanes
(docetaxel).rTheoretical→Also seeTABLE 15p. 850
▶Mitotaneis predicted to decrease the concentration of
temsirolimus. Avoid.rStudy→Also seeTABLE 15p. 850▶Mitotanedecreases the exposure totetracyclines(doxycycline).
Monitor and adjust dose.oStudy
▶Mitotaneis predicted to markedly decrease the exposure to
ticagrelor. Avoid.rStudy
▶Mitotaneis predicted to decrease the exposure totivozanib.
rStudy
▶Mitotaneis predicted to decrease the exposure totofacitinib.
Avoid.rStudy
▶Mitotaneis predicted to decrease the exposure totolvaptan.
Avoid.rStudy
▶Mitotaneis predicted to decrease the exposure totoremifene.
Adjust dose.oStudy
▶Mitotaneis predicted to decrease the exposure totrabectedin.
Avoid.rTheoretical→Also seeTABLE 15p. 850
▶Mitotaneis predicted to decrease the exposure tovandetanib.
Avoid.oStudy
▶Mitotaneis predicted to moderately decrease the exposure to
velpatasvir. Avoid.rStudy
▶Mitotaneis predicted to decrease the exposure tovemurafenib.
Avoid.rTheoretical
▶Mitotaneis predicted to decrease the exposure tovenetoclax.
Avoid.rStudy
▶Mitotaneis predicted to decrease the exposure tovinca
alkaloids(vinblastine, vincristine, vindesine).rTheoretical→
Also seeTABLE 15p. 850
▶Mitotaneis predicted to decrease the exposure tovinca
alkaloids(vinflunine). Avoid.rTheoretical→Also see
TABLE 15p. 850
▶Mitotaneis predicted to decrease the exposure tovinca
alkaloids(vinorelbine). Use with caution or avoid.r
Theoretical→Also seeTABLE 15p. 850
▶Mitotaneis predicted to decrease the exposure tovismodegib.
Avoid.oTheoretical→Also seeTABLE 15p. 850
▶Mitotaneis predicted to decrease the exposure tovortioxetine.
Monitor and adjust dose.oStudy
▶Mitotaneis predicted to decrease the concentration of
voxilaprevir. Avoid.rStudy
▶Mitotaneis predicted to decrease the exposure tozopiclone.
Adjust dose.oStudy
Mitoxantrone→see anthracyclines
Mivacurium→see neuromuscular blocking drugs, non-depolarising
Mizolastine→see antihistamines, non-sedating
Moclobemide→seeTABLE 13p. 850 (serotonin syndrome)
FOOD AND LIFESTYLEMoclobemide is claimed to cause less
potentiation of the pressor effect of tyramine than the
traditional (irreversible) MAOIs, but patients should avoid
consuming large amounts of tyramine-rich foods (such as
mature cheese, salami, pickled herring,Bovril®,Oxo®,
Marmite®or any similar meat or yeast extract or fermented
soya bean extract, and some beers, lagers or wines).
▶Moclobemideis predicted to increase the risk of a hypertensive
crisis when given withamfetamines. Avoid.r
Theoretical→Also seeTABLE 13p. 850
▶Moclobemideis predicted to increase the risk of severe
hypertension when given withbupropion. Avoid.r
Theoretical→Also seeTABLE 13p. 850
▶Moclobemideis predicted to increase the exposure to
cilostazol.oTheoretical
▶Moclobemidepotentially increases the exposure toclobazam.
Adjust dose.oTheoretical
▶Moclobemideis predicted to decrease the efficacy of
clopidogrel. Avoid.oStudy
▶Moclobemideis predicted to increase the exposure to
eliglustat. Avoid or adjust dose—consult product literature.
rTheoretical
▶H 2 receptor antagonists(cimetidine)increase the exposure to
moclobemide. Adjustmoclobemidedose.nStudy
▶Levodopaincreases the risk of side-effects when given with
moclobemide.oStudy
▶Moclobemideis predicted to increase the risk of side-effects
when given withlinezolid. Avoid and for 14 days after
stoppingmoclobemide.rTheoretical→Also seeTABLE 13
p. 850956 Mitotane—Moclobemide BNFC 2018 – 2019
Interactions|Appendix 1A1